<DOC>
	<DOCNO>NCT00093080</DOCNO>
	<brief_summary>The purpose study assess efficacy ridaforolimus administer daily 5 consecutive day ( QDx5 ) every two week participant advance sarcoma .</brief_summary>
	<brief_title>Study AP23573/MK-8669 ( Ridaforolimus ) , A Mammalian Target Rapamycin ( mTOR ) Inhibitor , Participants With Advanced Sarcoma ( MK-8669-018 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients ≥15 year age metastatic and/or unresectable sarcoma follow histological subgroup : Bone sarcoma , osteosarcoma Ewings sarcoma ; Leiomyosarcoma ; Liposarcomas ; Any soft tissue sarcoma except gastrointestinal stromal tumor ( GIST ) . Patients welldifferentiated liposarcoma desmoid tumor must demonstrate progressive disease within previous 6 month Presence least one measurable lesion : Can accurately measure least one dimension long diameter ≥20 mm use conventional technique ≥10 mm spiral computerize tomography ( CT ) scan ( otherwise least twice reconstruction interval CT magnetic resonance image [ MRI ] scan ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Minimum life expectancy 3 month Adequate renal hepatic function , specify protocol Adequate bone marrow function , specify protocol Serum cholesterol &lt; 350 mg/dL triglyceride &lt; 400 mg/dL Male female patient surgically sterile postmenopausal must agree use reliable method birth control duration study 30 day last dose study drug Able understand give write informed consent Women pregnant lactate Presence brain metastasis Prior therapy rapamycin , rapamycin analogue tacrolimus Prior anticancer treatment ( chemotherapy , radiotherapy , hormonal , immunotherapy , biological response modifier , signal transduction inhibitor , etc ) within 4 week prior first dose ridaforolimus Ongoing toxicity associate prior anticancer therapy ( except peripheral neuropathy ≤ grade 1 National Cancer Institute ( NCI ) toxicity criterion ) Another primary malignancy within past three year ( except nonmelanoma skin cancer cervical carcinoma situ ) Known suspect hypersensitivity drug formulate polysorbate 80 ( Tween ) excipient contain study drug Known Grade 3 4 hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) Significant uncontrolled cardiovascular disease Active infection require systemic therapy Known human immunodeficiency virus ( HIV ) infection Treatment investigational agent within 4 week prior first dose ridaforolimus Concurrent treatment immunosuppressive agent prescribed corticosteroid stable dos 2 week prior first plan dose study drug Inadequate recovery prior surgical procedure undergone major surgical procedure within 2 week prior first dose ridaforolimus Presence lifethreatening illness organ system dysfunction , opinion Investigator , would either compromise patient 's safety interfere evaluate safety study drug</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Metastatic and/or unresectable soft tissue</keyword>
</DOC>